E. Jenny Heathcote

11.9k total citations · 6 hit papers
66 papers, 8.0k citations indexed

About

E. Jenny Heathcote is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, E. Jenny Heathcote has authored 66 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hepatology, 57 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in E. Jenny Heathcote's work include Hepatitis C virus research (50 papers), Hepatitis B Virus Studies (46 papers) and Liver Disease Diagnosis and Treatment (44 papers). E. Jenny Heathcote is often cited by papers focused on Hepatitis C virus research (50 papers), Hepatitis B Virus Studies (46 papers) and Liver Disease Diagnosis and Treatment (44 papers). E. Jenny Heathcote collaborates with scholars based in Canada, United States and United Kingdom. E. Jenny Heathcote's co-authors include Anna S. Lok, Jay H. Hoofnagle, Zachary Goodman, Carol Brosgart, Patrick Marcellin, Mario Rizzetto, G. Kitis, Ting‐Tsung Chang, Seng Gee Lim and Stephanos J. Hadziyannis and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

E. Jenny Heathcote

65 papers receiving 7.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

2003 749 citations Stephanos J. Hadziyannis, E. Jenny Heathcote et al. New England Journal of Medicine profile →
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

2006 703 citations Stephanos J. Hadziyannis, E. Jenny Heathcote et al. Gastroenterology profile →
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis

2000 682 citations E. Jenny Heathcote, Mitchell L. Shiffman et al. New England Journal of Medicine profile →
Management of hepatitis B: 2000—Summary of a workshop

2001 610 citations E. Jenny Heathcote et al. Gastroenterology profile →
Long-term safety of lamivudine treatment in patients with chronic hepatitis B

2003 596 citations Ching‐Lung Lai, E. Jenny Heathcote et al. Gastroenterology profile →
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

2007 578 citations Ching‐Lung Lai, E. Jenny Heathcote et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Jenny Heathcote Canada	33	7.2k	7.1k	895	546	289	66	8.0k
Savino Bruno Italy	38	5.9k 0.8×	5.7k 0.8×	625 0.7×	508 0.9×	407 1.4×	133	7.0k
Marc Bourlière France	49	7.6k 1.1×	7.0k 1.0×	1.3k 1.5×	462 0.8×	499 1.7×	305	8.8k
Alessandra Mangia Italy	45	6.4k 0.9×	6.1k 0.9×	759 0.8×	500 0.9×	618 2.1×	202	7.7k
Antonina Smedile Italy	41	6.6k 0.9×	6.7k 0.9×	592 0.7×	584 1.1×	413 1.4×	199	8.1k
Paul J. Pockros United States	50	6.5k 0.9×	6.2k 0.9×	1.1k 1.2×	580 1.1×	650 2.2×	190	8.5k
Robert P. Perrillo United States	44	8.4k 1.2×	8.9k 1.3×	1.0k 1.1×	469 0.9×	621 2.1×	119	10.1k
Lennox J. Jeffers United States	41	6.4k 0.9×	6.4k 0.9×	738 0.8×	1.1k 2.0×	294 1.0×	136	8.3k
Chuan–Mo Lee Taiwan	40	4.3k 0.6×	4.3k 0.6×	505 0.6×	780 1.4×	236 0.8×	122	5.9k
George Marinos Australia	25	7.0k 1.0×	6.2k 0.9×	924 1.0×	344 0.6×	753 2.6×	63	8.0k
E. Jenny Heathcote Canada	40	7.8k 1.1×	7.4k 1.0×	600 0.7×	1.1k 2.0×	586 2.0×	85	9.0k

Countries citing papers authored by E. Jenny Heathcote

Since Specialization

Citations

This map shows the geographic impact of E. Jenny Heathcote's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Jenny Heathcote with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Jenny Heathcote more than expected).

Fields of papers citing papers by E. Jenny Heathcote

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Jenny Heathcote. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Jenny Heathcote. The network helps show where E. Jenny Heathcote may publish in the future.

Co-authorship network of co-authors of E. Jenny Heathcote

This figure shows the co-authorship network connecting the top 25 collaborators of E. Jenny Heathcote. A scholar is included among the top collaborators of E. Jenny Heathcote based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Jenny Heathcote. E. Jenny Heathcote is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ho, Edith Y., Thomas Yau, Franck Rousseau, E. Jenny Heathcote, & George Lau. (2015). Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatology International. 9(2). 224–230. 15 indexed citations

Wong, William, Gloria Woo, E. Jenny Heathcote, & Murray Krahn. (2011). Cost effectiveness of screening immigrants for hepatitis B. Liver International. 31(8). 1179–1190. 41 indexed citations

John‐Baptiste, Ava, George Tomlinson, Mel Krajden, et al.. (2009). Sustained Responders Have Better Quality of Life and Productivity Compared With Treatment Failures Long After Antiviral Therapy for Hepatitis C. The American Journal of Gastroenterology. 104(10). 2439–2448. 72 indexed citations

Craxı̀, Antonio, Sanaa M. Kamal, Rami Moucari, et al.. (2009). The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver International. 30(3). 342–355. 133 indexed citations

Heathcote, E. Jenny. (2008). Evolution and Presentation of Chronic Hepatitis B Infection. The American Journal of Medicine. 121(12). i–OBC. 17 indexed citations

Marcellin, Patrick, George Lau, Stefan Zeuzem, et al.. (2008). Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a. Liver International. 28(4). 477–485. 51 indexed citations

Heathcote, E. Jenny. (2007). Diagnosis and Management of Cholestatic Liver Disease. Clinical Gastroenterology and Hepatology. 5(7). 776–782. 49 indexed citations

Veldt, Bart J., E. Jenny Heathcote, Heiner Wedemeyer, et al.. (2007). Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis. Annals of Internal Medicine. 147(10). 677–684. 438 indexed citations

Heathcote, E. Jenny. (2007). Antiviral therapy: chronic hepatitis C. Journal of Viral Hepatitis. 14(s1). 82–88. 32 indexed citations

10.

Feld, Jordan J. & E. Jenny Heathcote. (2006). Hepatitis B e Antigen-Positive Chronic Hepatitis B: Natural History and Treatment. Seminars in Liver Disease. 26(2). 116–129. 24 indexed citations

11.

Flink, Hajo J., Bettina E. Hansen, E. Jenny Heathcote, et al.. (2006). Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine. The American Journal of Gastroenterology. 101(11). 2523–2529. 21 indexed citations

12.

Hadziyannis, Stephanos J., N.C. Tassopoulos, E. Jenny Heathcote, et al.. (2005). Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B. New England Journal of Medicine. 352(26). 9 indexed citations

13.

Rizzetto, Mario, Robert Goldin, Rafael Esteban, et al.. (2004). Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. Journal of Hepatology. 42(2). 173–179. 66 indexed citations

14.

Peters, Marion G., Hie‐Won Hann, Paul Martin, et al.. (2003). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).. Gastroenterology. 126(1). 91–101. 440 indexed citations

15.

Heathcote, E. Jenny. (2003). Treatment Considerations in Patients With Hepatitis C and Cirrhosis. Journal of Clinical Gastroenterology. 37(5). 395–398. 14 indexed citations

16.

Heathcote, E. Jenny, Mitchell L. Shiffman, W. Graham E. Cooksley, et al.. (2000). Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis. New England Journal of Medicine. 343(23). 1673–1680. 682 indexed citations breakdown →

17.

Puri, Veena, Arthur Bookman, Erik Yeo, Ross Cameron, & E. Jenny Heathcote. (1999). Antiphospholipid antibody syndrome associated with hepatitis C infection.. PubMed. 26(2). 509–10. 13 indexed citations

18.

Lindor, Keith D., et al.. (1998). Primary biliary cirrhosis : from pathogenesis to clinical treatment. Kluwer Academic eBooks. 15 indexed citations

19.

Yim, Colina, et al.. (1996). The Interaction of Human Immunodeficiency Virus Infection and Hepatitis B Virus Infection in Infected Homosexual Men. Journal of Clinical Gastroenterology. 22(4). 299–304. 38 indexed citations

20.

Wanless, Ian R., Ariel Katz, Peter J. Scheuer, et al.. (1994). Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.. Gut. 35(2). 260–265. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact